A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study aims to examine the safety, tolerability and pharmacokinetics of transdermal
delivery of human Growth Hormone (hGH or somatropin) using the ViaDerm device in adult
patients with Growth Hormone Deficiency Syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Neuroscience, Inc.
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries TransPharma Medical